Format

Send to

Choose Destination
Ann Rheum Dis. 2017 Dec;76(12):1992-2000. doi: 10.1136/annrheumdis-2017-211206. Epub 2017 Aug 5.

Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece.

Author information

1
Department of Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Greece.
2
Laboratory of Autoimmunity and Inflammation, Institute of Molecular Biology and Biotechnology, FORTH, Heraklion, Greece.
3
4th Department of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
4
Department of Social Medicine, University of Crete School of Medicine, Heraklion, Greece.
5
Department of Nephrology, General Hospital of Chania, Chania, Greece.
6
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
7
Department of Genetics and Cell Biology, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
8
Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece.
9
Medical School, University of Cyprus, Nicosia, Cyprus.
10
Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

Abstract

OBJECTIVES:

Several population-based studies on systemic lupus erythematosus (SLE) have been reported, yet community-based, individual-case validated, comprehensive reports are missing. We studied the SLE epidemiology and burden on the island of Crete during 1999-2013.

METHODS:

Multisource case-finding included patients ≥15 years old. Cases were ascertained by the ACR 1997, SLICC 2012 criteria and rheumatologist diagnosis, and validated through synthesis of medical charts, administrative and patient-generated data.

RESULTS:

Overall age-adjusted/sex-adjusted incidence was 7.4 (95% CI 6.8 to 7.9) per 100 000 persons/year, with stabilising trends in women but increasing in men, and average (±SD) age of diagnosis at 43 (±15) years. Adjusted and crude prevalence (December 2013) was 123.4 (113.9 to 132.9) and 143 (133 to 154)/105 (165/105 in urban vs 123/105 in rural regions, p<0.001), respectively. Age-adjusted/sex-adjusted nephritis incidence was 0.6 (0.4 to 0.8) with stable trends, whereas that of neuropsychiatric SLE was 0.5 (0.4 to 0.7) per 100 000 persons/year and increasing. Although half of prevalent cases had mild manifestations, 30.5% developed organ damage after 7.2 (±6.6) years of disease duration, with the neuropsychiatric domain most frequently afflicted, and 4.4% of patients with nephritis developed end-stage renal disease. The ACR 1997 and SLICC 2012 classification criteria showed high concordance (87%), yet physician-based diagnosis occurred earlier than criteria-based in about 20% of cases.

CONCLUSIONS:

By the use of a comprehensive methodology, we describe the full spectrum of SLE from the community to tertiary care, with almost half of the cases having mild disease, yet with significant damage accrual. SLE is not rare, affects predominantly middle-aged women and is increasingly recognised in men. Neuropsychiatric disease is an emerging frontier in lupus prevention and care.

KEYWORDS:

epidemiology; incidence; lupus nephritis; neuropsychiatric lupus; prevalence

PMID:
28780511
DOI:
10.1136/annrheumdis-2017-211206
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center